Evotec to pause commercial manufacturing of Vertex's povetacicept at J.POD Redmond

Evotec SE reported it will pause commercial manufacturing of Vertex Pharmaceuticals' investigational drug povetacicept at its J.POD Redmond site, a temporary suspension required to accommodate construction and integration of a third production train scheduled for 2027. The announcement came in Evotec's third-quarter 2026 financial and operational update.

Detected & updated continuously · Source: Nebula